Program
SHR-1826
A development code. Also written as “SHR-1826;Adebrelimab;SHR-8068;Bevacizumab”, “Adebrelimab Injection combined with SHR-1826 Injection combined with SHR-8068 Injection” and “HRS-7058 + SHR-1826”.
In Jiangsu HengRui Medicine's pipeline, c-Met ADC
. Its studies are mostly in Carcinoma, Non-Small-Cell Lung, led by Jiangsu HengRui Medicine.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Jiangsu HengRui Medicine | 77 open or running | phase 2since Nov 19, 2024 | Oct 16, 2023 | Dec 2026phase 2 · NCT06844474 |
- Named in Jiangsu HengRui Medicine’s own pipeline as
SHR-1826
, phase 2, as of Jul 31, 2026 (source).
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Oct 16, 2023First study: phase 1 study in Advanced Solid TumorsFirst studyNCT06094556 · 240 planned · China
- Nov 19, 2024Phase 2 study in Advanced Solid TumorsNCT06703177 · 876 planned · China
- Dec 24, 2024Phase 2 study in Carcinoma, Non-Small-Cell LungNCT06754930 · 400 planned · China
- Feb 19, 2025Phase 2 study in NSCLCNCT06844474 · 300 planned · China
- Apr 1, 2025Phase 2 study in Advanced Malignant TumourNCT06915142 · 300 planned · China
- Mar 18, 2026Phase 2 study in Carcinoma, Non-Small-Cell LungNCT07489716 · 90 planned · China
- Jul 10, 2026Phase 2 study in Resectable Non-small Cell Lung CancerNCT07704645 · 180 planned · China
Ahead
- Dec 2026Primary completion: phase 2 study in Advanced Malignant TumourNCT06915142
- Dec 2026Primary completion: phase 2 study in NSCLCNCT06844474
- Jun 30, 2027Primary completion: phase 1 study in Advanced Solid TumorsNCT06094556
- Dec 2027Primary completion: phase 2 study in Carcinoma, Non-Small-Cell LungNCT06754930
TargetBeta
“c-Met ADC”the company's pipeline, read by Claude · source
Other programs on MET
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| cabozantinibrule | Exelixis | phase 4 | 36 |
| Crizotinibrule | Pfizer | phase 4 | 31 |
| telisotuzumab adizutecan | AbbVie | phase 3 | 18 |
| zanzalintinibrule | Exelixis | phase 3 | 17 |
| amivantamabrule | Johnson & Johnson | phase 3 | 16 |
| vebreltinibrule | beijing-pearl-biotechnology-limited-liability-company | phase 3 | 9 |
| glumetinibrule | Haihe Biopharma | phase 3 | 8 |
| vilzemetkib | Sino Biopharmaceutical | phase 3 | 8 |
| dalmelitinib | Hansoh Pharmaceutical Group | phase 3 | 7 |
| bafisontamabrule | shanghai-epimab-biotherapeutics-co-ltd | phase 3 | 5 |
| HS-20117 | Hansoh Pharmaceutical Group | phase 3 | 3 |
| pamvatamigrule | Betta Pharmaceuticals | phase 2 | 5 |
Studies
All 7 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07704645Resectable Non-small Cell Lung Cancer · China | 2 | Not yet recruiting | Jun 2028 | 180 |
| NCT07489716Carcinoma, Non-Small-Cell Lung · China | 2 | Recruiting | Aug 2028 | 90 |
| NCT06915142Advanced Malignant Tumour · China | 2 | Recruiting | Dec 2026 | 300 |
| NCT06844474NSCLC · China | 2 | Recruiting | Dec 2026 | 300 |
| NCT06754930Carcinoma, Non-Small-Cell Lung · China | 2 | Recruiting | Dec 2027 | 400 |
| NCT06703177Advanced Solid Tumors · China | 2 | Recruiting | Jan 1, 2026 | 876 |
| NCT06094556Advanced Solid Tumors · China | 1 | Recruiting | Jun 30, 2027 | 240 |
How it is read
Names in the registry
- “SHR-1826”, 4 entries
- “SHR-1826;Adebrelimab;SHR-8068;Bevacizumab”, 1 entry
- “Adebrelimab Injection combined with SHR-1826 Injection combined with SHR-8068 Injection”, 1 entry
- “HRS-7058 + SHR-1826”, 1 entry
- “HRS-7058 + SHR-1826 + SHR-1316”, 1 entry
Codes read as this program: SHR1826.
Conditions, from the studies’ own filings
- Carcinoma, Non-Small-Cell Lung, 3 studies
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.